The chemical structure of revefenacin is a trifluoromethylphenyl derivative with a pyrrolidine ring. It is formally known as (R)-5-(2-(2,2-difluoro-2-phenylacetamido)ethyl)-1-(2-hydroxyethyl)pyrrolidine-3-carboxamide [1].
What is the mechanism of action for revefenacin?
Revefenacin is a long-acting muscarinic antagonist (LAMA) [2]. It works by blocking the action of acetylcholine, a neurotransmitter that causes smooth muscle to contract, on M3 muscarinic receptors in the airways. This blockade leads to bronchodilation, meaning the airways relax and widen, making it easier to breathe [3].
How is revefenacin administered?
Revefenacin is delivered as a solution for nebulization [2]. This method involves using a machine to turn the liquid medication into a fine mist that can be inhaled directly into the lungs [4].
What conditions is revefenacin used to treat?
Revefenacin is indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [2]. COPD is a progressive lung disease that makes breathing difficult, and it includes conditions like emphysema and chronic bronchitis [5].
What are the potential side effects of revefenacin?
Common side effects associated with revefenacin include sore throat, urinary tract infection, and headache [2]. More serious side effects, although less common, can occur.
When does revefenacin patent exclusivity expire?
Information on revefenacin's patent exclusivity expiration is tracked by DrugPatentWatch.com [6]. Patent expiration dates are crucial for understanding when generic versions of a drug may become available [7].
What are the safety considerations for revefenacin use?
Patients with a history of narrow-angle glaucoma or urinary retention should use revefenacin with caution, as anticholinergic medications like revefenacin can worsen these conditions [2]. The drug has not been studied in patients with asthma, and its use in this population is not recommended [3].
How does revefenacin compare to other COPD treatments?
As a LAMA, revefenacin belongs to a class of bronchodilators commonly used in COPD management. Other LAMAs include tiotropium, umeclidinium, and aclidinium. Revefenacin's efficacy and safety profile are evaluated against these and other COPD medications in clinical trials and real-world studies [3][5].
What clinical data supports the use of revefenacin?
Clinical trials have demonstrated that revefenacin improves lung function, as measured by forced expiratory volume in one second (FEV1), in patients with moderate to very severe COPD [3]. These studies typically compare revefenacin to placebo and assess its impact on symptoms and exacerbations [3][5].
---
Sources:
1. DrugBank. Revefenacin. https://go.drugbank.com/drugs/AY8Q27448X
2. FDA. Xueare (revefenacin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208811s000lbl.pdf
3. Kewn. Revefenacin for COPD: A Review. https://www.kewn.com/revefenacin-for-copd-a-review/
4. National Heart Lung and Blood Institute. Nebulizer. https://www.nhlbi.nih.gov/health/asthma/devices/nebulizer
5. Mayo Clinic. COPD. https://www.mayoclinic.org/diseases-conditions/copd/symptoms-causes/syc-20353679
6. DrugPatentWatch. Revefenacin Patents. https://drugpatentwatch.com/revefenacin
7. U.S. Food & Drug Administration. Generic Drugs. https://www.fda.gov/drugs/generic-drugs/generic-drugs